Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial
| Autor: | William F. Chaplin, Nadia Tanel, Evdokia Anagnostou, Stacey Wasserman, Jennifer A. Bartz, Lauren Pepa, Eric Hollander, Azadeh Kushki, Danielle Halpern, Latha Soorya, A. Ting Wang |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Autism
Placebo Oxytocin lcsh:RC346-429 law.invention 03 medical and health sciences 0302 clinical medicine Quality of life (healthcare) Yale–Brown Obsessive Compulsive Scale Developmental Neuroscience Randomized controlled trial law Social cognition Medicine Adults Molecular Biology lcsh:Neurology. Diseases of the nervous system medicine.diagnostic_test business.industry Research Cognition medicine.disease 030227 psychiatry 3. Good health Clinical trial Psychiatry and Mental health Autism spectrum disorder business 030217 neurology & neurosurgery Developmental Biology Clinical psychology |
| Zdroj: | Molecular Autism Molecular Autism, Vol 3, Iss 1, p 16 (2012) |
| ISSN: | 2040-2392 |
| Popis: | Background There are no effective medications for the treatment of social cognition/function deficits in autism spectrum disorder (ASD), and adult intervention literature in this area is sparse. Emerging data from animal models and genetic association studies as well as early, single-dose intervention studies suggest that the oxytocin system may be a potential therapeutic target for social cognition/function deficits in ASD. The primary aim of this study was to examine the safety/therapeutic effects of intranasal oxytocin versus placebo in adults with ASD, with respect to the two core symptom domains of social cognition/functioning and repetitive behaviors. Methods This was a pilot, randomized, double-blind, placebo-controlled, parallel design trial of intranasal oxytocin versus placebo in 19 adults with ASD (16 males; 33.20 ± 13.29 years). Subjects were randomized to 24 IU intranasal oxytocin or placebo in the morning and afternoon for 6 weeks. Measures of social function/cognition (the Diagnostic Analysis of Nonverbal Accuracy) and repetitive behaviors (Repetitive Behavior Scale Revised) were administered. Secondary measures included the Social Responsiveness Scale, Reading-the-Mind-in-the-Eyes Test and the Yale Brown Obsessive Compulsive Scale – compulsion subscale and quality of life (World Health Organization Quality of Life Questionnaire – emotional/social subscales). Full-information maximum-likelihood parameter estimates were obtained and tested using mixed-effects regression analyses. Results Although no significant changes were detected in the primary outcome measures after correcting for baseline differences, results suggested improvements after 6 weeks in measures of social cognition (Reading-the-Mind-in-the-Eyes Test, p = 0.002, d = 1.2), and quality of life (World Health Organization Quality of Life Questionnaire – emotion, p = 0.031, d = 0.84), both secondary measures. Oxytocin was well tolerated and no serious adverse effects were reported. Conclusions This pilot study suggests that there is therapeutic potential to daily administration of intranasal oxytocin in adults with ASD and that larger and longer studies are warranted. Trial registration NCT00490802 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|